Atlas Venture Life Science Advisors, LLC Xilio Therapeutics, Inc. Transaction History
Atlas Venture Life Science Advisors, LLC
- $799 Million
- Q1 2024
A detailed history of Atlas Venture Life Science Advisors, LLC transactions in Xilio Therapeutics, Inc. stock. As of the latest transaction made, Atlas Venture Life Science Advisors, LLC holds 992,912 shares of XLO stock, worth $893,620. This represents 0.13% of its overall portfolio holdings.
Number of Shares
992,912
Previous 2,759,344
64.02%
Holding current value
$893,620
Previous $1.52 Million
29.33%
% of portfolio
0.13%
Previous 0.24%
Shares
2 transactions
Others Institutions Holding XLO
# of Institutions
32Shares Held
10MCall Options Held
0Put Options Held
0-
Bain Capital Life Sciences Investors, LLC Boston, MA2.81MShares$2.52 Million0.46% of portfolio
-
River Vest Venture Management LLC St. Louis, MO1.44MShares$1.3 Million19.12% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD1.44MShares$1.3 Million0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA903KShares$812,2770.0% of portfolio
-
Aju Ib Investment Co., Ltd. Seoul, M5668KShares$600,9673.33% of portfolio
About Xilio Therapeutics, Inc.
- Ticker XLO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 27,471,600
- Market Cap $24.7M
- Description
- Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine prog...